Novo Nordisk's weight-loss drug semaglutide, sold as the once-weekly Wegovy shot, was effective as a daily pill in a study.

People with obesity or who were overweight and had another health problem lost an average of 15.1% of their body weight when assigned to take the pill, compared with a 2.4% loss in a group given a placebo, the Danish drugmaker said. Both groups also made lifestyle changes.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.